Jensen Huang, CEO of Nvidia (NVDA), revealed details around a number of announcements on new technologies on Monday at the Computex tech expo in Taipei, Taiwan.

This included showcasing Nvidia Isaac GR00T-Dreams, which the company described as a blueprint that helps generate large amounts of synthetic motion data that physical artificial intelligence (AI) developers can use to teach robots new behaviours.

In addition to its robotics capabilities, Nvidia unveiled its new NVLink Fusion offering, which allows customers to build custom servers using Nvidia’s Grace CPU and a third-party AI chip paired with Nvidia’s various server infrastructure offerings.

Nvidia shares were down 2.5% in pre-market trading on Monday, though the stock has seen a stronger performance more recently and is up 29% over the past month.

Last week, Huang said during an investment forum in Saudi Arabia — which was attended by US president Donald Trump and other Big Tech CEOs — that the chipmaker will ship its semiconductors to Saudi Arabian artificial intelligence company Humain for its massive data centre plans.

Hong Kong-listed shares in Alibaba (9988.HK) fell 3% on Monday, following a report over the weekend that the Trump administration had raised concerns about a potential deal between the Chinese tech giant and iPhone-maker Apple (AAPL).

The New York Times reported on Saturday that the White House and congressional officials have been scrutinising Apple's plan to strike a deal with Alibaba to make its AI available on iPhones in China.

Spokespeople for the White House, Alibaba and Apple had not responded to Yahoo Finance UK's request for comment at the time of writing.

The report further weighed on Alibaba shares, which dropped last week after the company's earnings missed estimates.

Fourth-quarter revenue of 236.45 billion yuan was below analyst expectations of 237.24 billion yuan (£24.57bn), according to a Reuters report. Adjusted earnings of 12.52 yuan per American Depositary Share also just missed estimates of 12.94 yuan.

Shares in biotechnology company Novavax (NVAX) surged 17% in pre-market trading on Monday, after the US Food and Drug Administration (FDA) approved its Covid-19 vaccine, albeit with certain conditions.

In a letter issued on Friday, the FDA said that the vaccine was approved for people aged 65 and over, and those aged 12 and over if they had at least one underlying condition that put them at high risk of severe illness from Covid.